There is a revolution in care and that is having an impact on large established healthcare organizations and Life Sciences companies. The new healthcare bill (ACA) passed by Congress in 2010 and current changes to the ACA will have wide and deep ramifications to companies in the Healthcare and Life Sciences space. Current trends in the space reflect increase in costs and an environment where the government may be much more involved in the delivery of healthcare and in the regulatory process for approving new drugs and medical devices will have a significant impact on the companies in the space and on the pace and type of new discoveries..
Demographic changes in the US and in the developed world in general reflect an aging population that will place increasing demands on life-extending drugs, medical devices to address this aging population needs and technology and processes to deliver care and services. New infrastructure and technologies that support the delivery of services and products to the market will be emphasized not only because of an increasingly aging population but because of the demands on cost reduction, government involvement and profit margin pressures.
A drive towards “personalized” medicine will accelerate with tools and processes that match the best treatment to a particular patient increasingly taking center stage. This drive will have a substantial impact on the manner in which companies currently conduct their Research and Development activities, how costs are accounted for and allocated and risk management and performance monitoring process and technologies.
Representative Services provided in the industry